DDInter1185 DDInter1376
Methyldopa, or α-methyldopa, is a centrally acting sympatholytic agent and an antihypertensive agent. It is an analog of DOPA (3,4‐hydroxyphenylanine), and it is a prodrug, meaning that the drug requires biotransformation to an active metabolite for therapeutic effects. Methyldopa works by binding to alpha(α)-2 adrenergic receptors as an agonist, leading to the inhibition of adrenergic neuronal outflow and reduction of vasoconstrictor adrenergic signals. Methyldopa exists in two isomers D-α-methyldopa and L-α-methyldopa, which is the active form. First introduced in 1960 as an antihypertensive agent, methyldopa was considered to be useful in certain patient populations, such as pregnant women and patients with renal insufficiency. Since
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Methyldopa {u} (Compound) resembles {v} (Compound) Norepinephrine
Methyldopa {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epinephrine
Methyldopa {u} (Compound) resembles {v} (Compound) Droxidopa
Methyldopa {u} (Compound) treats {v} (Disease) hypertension
Methyldopa {u} (Compound) binds {v} (Gene) SLC15A1
Methyldopa {u} (Compound) upregulates {v} (Gene) NFATC3
Methyldopa {u} (Compound) downregulates {v} (Gene) ADI1
Methyldopa {u} (Compound) causes {v} (Side Effect) Rash
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Methyldopa {u} may cause a minor interaction that can limit clinical effects when taken with {v} Acetohexamide
Methyldopa (Compound) resembles Norepinephrine (Compound)
Methyldopa may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine
Methyldopa (Compound) resembles Droxidopa (Compound)
Methyldopa (Compound) treats hypertension (Disease)
Methyldopa (Compound) binds SLC15A1 (Gene)
Methyldopa (Compound) upregulates NFATC3 (Gene)
Methyldopa (Compound) downregulates ADI1 (Gene)
Methyldopa (Compound) causes Rash (Side Effect)
Methyldopa may cause a minor interaction that can limit clinical effects when taken with Glipizide
Methyldopa may cause a minor interaction that can limit clinical effects when taken with Acetohexamide